Cargando…
Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate
BACKGROUND: Mutations in isocitrate dehydrogenase 1 (IDH1) occur in various types of cancer and induce metabolic alterations resulting from the neomorphic activity that causes production of D-2-hydroxyglutarate (D-2-HG) at the expense of α-ketoglutarate (α-KG) and NADPH. To overcome metabolic stress...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526618/ https://www.ncbi.nlm.nih.gov/pubmed/31139406 http://dx.doi.org/10.1186/s40170-019-0198-7 |
_version_ | 1783419926107652096 |
---|---|
author | Peeters, Tom H. Lenting, Krissie Breukels, Vincent van Lith, Sanne A. M. van den Heuvel, Corina N. A. M. Molenaar, Remco van Rooij, Arno Wevers, Ron Span, Paul N. Heerschap, Arend Leenders, William P. J. |
author_facet | Peeters, Tom H. Lenting, Krissie Breukels, Vincent van Lith, Sanne A. M. van den Heuvel, Corina N. A. M. Molenaar, Remco van Rooij, Arno Wevers, Ron Span, Paul N. Heerschap, Arend Leenders, William P. J. |
author_sort | Peeters, Tom H. |
collection | PubMed |
description | BACKGROUND: Mutations in isocitrate dehydrogenase 1 (IDH1) occur in various types of cancer and induce metabolic alterations resulting from the neomorphic activity that causes production of D-2-hydroxyglutarate (D-2-HG) at the expense of α-ketoglutarate (α-KG) and NADPH. To overcome metabolic stress induced by these alterations, IDH-mutated (IDH(mut)) cancers utilize rescue mechanisms comprising pathways in which glutaminase and glutamate dehydrogenase (GLUD) are involved. We hypothesized that inhibition of glutamate processing with the pleiotropic GLUD-inhibitor epigallocatechin-3-gallate (EGCG) would not only hamper D-2-HG production, but also decrease NAD(P)H and α-KG synthesis in IDH(mut) cancers, resulting in increased metabolic stress and increased sensitivity to radiotherapy. METHODS: We performed (13)C-tracing studies to show that HCT116 colorectal cancer cells with an IDH1(R132H) knock-in allele depend more on glutaminolysis than on glycolysis for the production of D-2-HG. We treated HCT116 cells, HCT116-IDH1(R132H) cells, and HT1080 cells (carrying an IDH1(R132C) mutation) with EGCG and evaluated D-2-HG production, cell proliferation rates, and sensitivity to radiotherapy. RESULTS: Significant amounts of (13)C from glutamate accumulate in D-2-HG in HCT116-IDH1(wt/R132H) but not in HCT116-IDH1(wt/wt). Preventing glutamate processing in HCT116-IDH1(wt/R132H) cells with EGCG resulted in reduction of D-2-HG production. In addition, EGCG treatment decreased proliferation rates of IDH1(mut) cells and at high doses sensitized cancer cells to ionizing radiation. Effects of EGCG in IDH-mutated cell lines were diminished by treatment with the IDH1(mut) inhibitor AGI-5198. CONCLUSIONS: This work shows that glutamate can be directly processed into D-2-HG and that reduction of glutamatolysis may be an effective and promising new treatment option for IDH(mut) cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40170-019-0198-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6526618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65266182019-05-28 Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate Peeters, Tom H. Lenting, Krissie Breukels, Vincent van Lith, Sanne A. M. van den Heuvel, Corina N. A. M. Molenaar, Remco van Rooij, Arno Wevers, Ron Span, Paul N. Heerschap, Arend Leenders, William P. J. Cancer Metab Research BACKGROUND: Mutations in isocitrate dehydrogenase 1 (IDH1) occur in various types of cancer and induce metabolic alterations resulting from the neomorphic activity that causes production of D-2-hydroxyglutarate (D-2-HG) at the expense of α-ketoglutarate (α-KG) and NADPH. To overcome metabolic stress induced by these alterations, IDH-mutated (IDH(mut)) cancers utilize rescue mechanisms comprising pathways in which glutaminase and glutamate dehydrogenase (GLUD) are involved. We hypothesized that inhibition of glutamate processing with the pleiotropic GLUD-inhibitor epigallocatechin-3-gallate (EGCG) would not only hamper D-2-HG production, but also decrease NAD(P)H and α-KG synthesis in IDH(mut) cancers, resulting in increased metabolic stress and increased sensitivity to radiotherapy. METHODS: We performed (13)C-tracing studies to show that HCT116 colorectal cancer cells with an IDH1(R132H) knock-in allele depend more on glutaminolysis than on glycolysis for the production of D-2-HG. We treated HCT116 cells, HCT116-IDH1(R132H) cells, and HT1080 cells (carrying an IDH1(R132C) mutation) with EGCG and evaluated D-2-HG production, cell proliferation rates, and sensitivity to radiotherapy. RESULTS: Significant amounts of (13)C from glutamate accumulate in D-2-HG in HCT116-IDH1(wt/R132H) but not in HCT116-IDH1(wt/wt). Preventing glutamate processing in HCT116-IDH1(wt/R132H) cells with EGCG resulted in reduction of D-2-HG production. In addition, EGCG treatment decreased proliferation rates of IDH1(mut) cells and at high doses sensitized cancer cells to ionizing radiation. Effects of EGCG in IDH-mutated cell lines were diminished by treatment with the IDH1(mut) inhibitor AGI-5198. CONCLUSIONS: This work shows that glutamate can be directly processed into D-2-HG and that reduction of glutamatolysis may be an effective and promising new treatment option for IDH(mut) cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40170-019-0198-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-20 /pmc/articles/PMC6526618/ /pubmed/31139406 http://dx.doi.org/10.1186/s40170-019-0198-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Peeters, Tom H. Lenting, Krissie Breukels, Vincent van Lith, Sanne A. M. van den Heuvel, Corina N. A. M. Molenaar, Remco van Rooij, Arno Wevers, Ron Span, Paul N. Heerschap, Arend Leenders, William P. J. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate |
title | Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate |
title_full | Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate |
title_fullStr | Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate |
title_full_unstemmed | Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate |
title_short | Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate |
title_sort | isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526618/ https://www.ncbi.nlm.nih.gov/pubmed/31139406 http://dx.doi.org/10.1186/s40170-019-0198-7 |
work_keys_str_mv | AT peeterstomh isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT lentingkrissie isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT breukelsvincent isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT vanlithsanneam isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT vandenheuvelcorinanam isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT molenaarremco isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT vanrooijarno isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT weversron isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT spanpauln isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT heerschaparend isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate AT leenderswilliampj isocitratedehydrogenase1mutatedcancersaresensitivetothegreenteapolyphenolepigallocatechin3gallate |